Our Science
Our Science
Cambium Bio develops novel regenerative therapy platforms in ophthalmology and tissue rejuvenation.
Cambium Bio develops novel regenerative therapy platforms in ophthalmology and tissue rejuvenation.
Aurarix® - fibrinogen-depleted human platelet lysate platform technology
Aurarix® - fibrinogen-depleted human platelet lysate platform technology
Aurarix® - fibrinogen-depleted human platelet lysate platform technology
Aurarix®
Platelets are anucleate cells produced in the bone marrow and found in human blood, rich in growth factors, cytokines, and other bioactive molecules.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
The technology was exclusively licensed from Emory University, GA, USA, in 2013 and is protected by the core patent "Compositions, Uses, And Preparation Of Platelet Lysates" (US 9,688,959 B2) in key geographies worldwide.
•
While HPL has not yet been approved for therapeutic use, it has been extensively utilized as a supplement in cell culture processes. Aurarix® FD-HPL technology has been sub-licensed to AventaCell, an affiliate of Cambium Bio's strategic partner Zheng Yang Biomedical Technology (ZYBT) in Taiwan, to manufacture and commercialise stem cell growth supplements.
•
The Aurarix® FD-HPL platform technology represents significant growth opportunities for Cambium Bio across various therapeutic markets including orthopaedics, wound healing, and multiple indications in ophthalmology.
•
Aurarix®
Platelets are anucleate cells produced in the bone marrow and found in human blood, rich in growth factors, cytokines, and other bioactive molecules.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
The technology was exclusively licensed from Emory University, GA, USA, in 2013 and is protected by the core patent "Compositions, Uses, And Preparation Of Platelet Lysates" (US 9,688,959 B2) in key geographies worldwide.
•
While HPL has not yet been approved for therapeutic use, it has been extensively utilized as a supplement in cell culture processes. Aurarix® FD-HPL technology has been sub-licensed to AventaCell, an affiliate of Cambium Bio's strategic partner Zheng Yang Biomedical Technology (ZYBT) in Taiwan, to manufacture and commercialise stem cell growth supplements.
•
The Aurarix® FD-HPL platform technology represents significant growth opportunities for Cambium Bio across various therapeutic markets including orthopaedics, wound healing, and multiple indications in ophthalmology.
•
Aurarix®
Platelets are anucleate cells produced in the bone marrow and found in human blood, rich in growth factors, cytokines, and other bioactive molecules.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
The technology was exclusively licensed from Emory University, GA, USA, in 2013 and is protected by the core patent "Compositions, Uses, And Preparation Of Platelet Lysates" (US 9,688,959 B2) in key geographies worldwide.
•
While HPL has not yet been approved for therapeutic use, it has been extensively utilized as a supplement in cell culture processes. Aurarix® FD-HPL technology has been sub-licensed to AventaCell, an affiliate of Cambium Bio's strategic partner Zheng Yang Biomedical Technology (ZYBT) in Taiwan, to manufacture and commercialise stem cell growth supplements.
•
The Aurarix® FD-HPL platform technology represents significant growth opportunities for Cambium Bio across various therapeutic markets including orthopaedics, wound healing, and multiple indications in ophthalmology.
•
Elate Ocular® - novel biologic eye drops to treat Dry Eye Disease, an "off-the-shelf natural tear"
Elate Ocular® - novel biologic eye drops to treat Dry Eye Disease, an "off-the-shelf natural tear"
Elate Ocular® - novel biologic eye drops to treat Dry Eye Disease, an "off-the-shelf natural tear"
Elate Ocular®
Derived from enriched fibrinogen-depleted human platelet lysate.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
pH and osmolarity closely mimic natural tears, but with a higher overall protein content.
•
Contains enriched levels of regenerative factors (EGF, PDGF, FGF), protease inhibitors, minerals and vitamins.
•
Supports improved ocular surface health.
•
Improved allogeneic version of Autologous Serum Tears (AST):
•
Enriched levels of growth factors.
•
Standardised composition for consistent quality.
•
Convenient, non-invasive dosing.
•
More scalable.
•
Potentially reimbursed.
•
Elate Ocular®
Derived from enriched fibrinogen-depleted human platelet lysate.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
pH and osmolarity closely mimic natural tears, but with a higher overall protein content.
•
Contains enriched levels of regenerative factors (EGF, PDGF, FGF), protease inhibitors, minerals and vitamins.
•
Supports improved ocular surface health.
•
Improved allogeneic version of Autologous Serum Tears (AST):
•
Enriched levels of growth factors.
•
Standardised composition for consistent quality.
•
Convenient, non-invasive dosing.
•
More scalable.
•
Potentially reimbursed.
•
Elate Ocular®
Derived from enriched fibrinogen-depleted human platelet lysate.
•
Aurarix® is a proprietary, enriched, fibrinogen-depleted, allogeneic human platelet lysate (“FD-HPL”), ethically sourced from healthy donors.
•
pH and osmolarity closely mimic natural tears, but with a higher overall protein content.
•
Contains enriched levels of regenerative factors (EGF, PDGF, FGF), protease inhibitors, minerals and vitamins.
•
Supports improved ocular surface health.
•
Improved allogeneic version of Autologous Serum Tears (AST):
•
Enriched levels of growth factors.
•
Standardised composition for consistent quality.
•
Convenient, non-invasive dosing.
•
More scalable.
•
Potentially reimbursed.
•
Mesenchymal stem cells for tissue regeneration:
Mesenchymal stem cells for tissue regeneration:
Mesenchymal stem cells for tissue regeneration:
Power of Secretome and MSCs to target pain
Cambium Bio utilizes Mesenchymal Signalling Cells, also known as Stromal cells or Stem cells (MSCs), derived from adipose tissue to target and repair tissue damage, reduce pain and calm inflammation.
•
To accomplish this, MSCs communicate via receptors and signalling molecules (collectively termed the 'Secretome') to resident tissue, restoring balance and resolving inflammatory states.
•
The Secretome includes a range of soluble proteins, growth factors, cytokines, chemokines, matrix proteins, lipids, microRNAs, and extracellular vesicles, including exosomes, which Cambium Bio has identified as playing key roles in modulating inflammation and promoting tissue repair.
•
MSCs 'repurpose' damaged and inflamed tissue by first homing to injury sites and then interacting with damaged cells and inflammatory molecules to alter the cellular microenvironment and resolve inflammation, rather than simply differentiating to replace lost cells.
•
Therapeutic areas. MSCs and their Secretome have broad potential to manage pain and inflammation across a range of conditions by targeting inflammatory processes at their source.
•
Power of Secretome and MSCs to target pain
Cambium Bio utilizes Mesenchymal Signalling Cells, also known as Stromal cells or Stem cells (MSCs), derived from adipose tissue to target and repair tissue damage, reduce pain and calm inflammation.
•
To accomplish this, MSCs communicate via receptors and signalling molecules (collectively termed the 'Secretome') to resident tissue, restoring balance and resolving inflammatory states.
•
The Secretome includes a range of soluble proteins, growth factors, cytokines, chemokines, matrix proteins, lipids, microRNAs, and extracellular vesicles, including exosomes, which Cambium Bio has identified as playing key roles in modulating inflammation and promoting tissue repair.
•
MSCs 'repurpose' damaged and inflamed tissue by first homing to injury sites and then interacting with damaged cells and inflammatory molecules to alter the cellular microenvironment and resolve inflammation, rather than simply differentiating to replace lost cells.
•
Therapeutic areas. MSCs and their Secretome have broad potential to manage pain and inflammation across a range of conditions by targeting inflammatory processes at their source.
•
Power of Secretome and MSCs to target pain
Cambium Bio utilizes Mesenchymal Signalling Cells, also known as Stromal cells or Stem cells (MSCs), derived from adipose tissue to target and repair tissue damage, reduce pain and calm inflammation.
•
To accomplish this, MSCs communicate via receptors and signalling molecules (collectively termed the 'Secretome') to resident tissue, restoring balance and resolving inflammatory states.
•
The Secretome includes a range of soluble proteins, growth factors, cytokines, chemokines, matrix proteins, lipids, microRNAs, and extracellular vesicles, including exosomes, which Cambium Bio has identified as playing key roles in modulating inflammation and promoting tissue repair.
•
MSCs 'repurpose' damaged and inflamed tissue by first homing to injury sites and then interacting with damaged cells and inflammatory molecules to alter the cellular microenvironment and resolve inflammation, rather than simply differentiating to replace lost cells.
•
Therapeutic areas. MSCs and their Secretome have broad potential to manage pain and inflammation across a range of conditions by targeting inflammatory processes at their source.
•
Osteoarthritis
Osteoarthritis, often referred to as the pain and inflammation around joints due to 'wear and tear', affects over 250 million people worldwide with onset typically around age 45. It can be linked to genetics, gender, age, obesity, overuse or joint injury.
•
While heterogeneous, rheumatologists generally believe osteoarthritis is primarily a disease of biomechanical changes. However, apart from rare erosive inflammatory subtypes, most OA patients exhibit inflammatory immune cell infiltrates in the synovial membrane.
•
Progenza™ aims to halt this inflammatory degradation and modify the underlying disease state, representing a $9.5B market opportunity in the US, EU and Japan alone.
•
A Phase 1 study of Progenza™ in OA patients (KL Grade 1-3) demonstrated significant treatment-related pain reductions for up to 12 months and cartilage volume stabilization in the target dose group.
•
Osteoarthritis
Osteoarthritis, often referred to as the pain and inflammation around joints due to 'wear and tear', affects over 250 million people worldwide with onset typically around age 45. It can be linked to genetics, gender, age, obesity, overuse or joint injury.
•
While heterogeneous, rheumatologists generally believe osteoarthritis is primarily a disease of biomechanical changes. However, apart from rare erosive inflammatory subtypes, most OA patients exhibit inflammatory immune cell infiltrates in the synovial membrane.
•
Progenza™ aims to halt this inflammatory degradation and modify the underlying disease state, representing a $9.5B market opportunity in the US, EU and Japan alone.
•
A Phase 1 study of Progenza™ in OA patients (KL Grade 1-3) demonstrated significant treatment-related pain reductions for up to 12 months and cartilage volume stabilization in the target dose group.
•
Osteoarthritis
Osteoarthritis, often referred to as the pain and inflammation around joints due to 'wear and tear', affects over 250 million people worldwide with onset typically around age 45. It can be linked to genetics, gender, age, obesity, overuse or joint injury.
•
While heterogeneous, rheumatologists generally believe osteoarthritis is primarily a disease of biomechanical changes. However, apart from rare erosive inflammatory subtypes, most OA patients exhibit inflammatory immune cell infiltrates in the synovial membrane.
•
Progenza™ aims to halt this inflammatory degradation and modify the underlying disease state, representing a $9.5B market opportunity in the US, EU and Japan alone.
•
A Phase 1 study of Progenza™ in OA patients (KL Grade 1-3) demonstrated significant treatment-related pain reductions for up to 12 months and cartilage volume stabilization in the target dose group.
•
Skin
Skin conditions are one of the nearest-term opportunities for cell-based regenerative medicine. Cambium Bio is focused on developing treatments to reduce pain and inflammation and accelerate healing and repair of painful conditions like burns, acne, wounds, and other chronic or acute injuries that most people encounter.
•
Sygenus has the potential to aid painful skin conditions by controlling inflammation, stimulating cell migration and proliferation, and improving scarring. It is currently in preclinical development.
•
Skin
Skin conditions are one of the nearest-term opportunities for cell-based regenerative medicine. Cambium Bio is focused on developing treatments to reduce pain and inflammation and accelerate healing and repair of painful conditions like burns, acne, wounds, and other chronic or acute injuries that most people encounter.
•
Sygenus has the potential to aid painful skin conditions by controlling inflammation, stimulating cell migration and proliferation, and improving scarring. It is currently in preclinical development.
•
Skin
Skin conditions are one of the nearest-term opportunities for cell-based regenerative medicine. Cambium Bio is focused on developing treatments to reduce pain and inflammation and accelerate healing and repair of painful conditions like burns, acne, wounds, and other chronic or acute injuries that most people encounter.
•
Sygenus has the potential to aid painful skin conditions by controlling inflammation, stimulating cell migration and proliferation, and improving scarring. It is currently in preclinical development.
•
